Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
LEXINGTON, Mass., April 30, 2018 -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2018 first quarter financial and operational results after the market closes on Tuesday, May 8, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, May 8, 2018 to discuss the financial results and other business developments.
Interested parties may access the live call via telephone by dialing 1-877-300-8521 (U.S.) or 1-412-317-6026 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com, in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.
About T2 Biosystems
T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, improves patient care and reduces the cost of healthcare by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and the T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance technology, or T2MR®. T2Bacteria Panel is commercially available in Europe and other countries that accept the CE Mark and is available for research use only in the U.S. For more information, please visit www.t2biosystems.com.
Media Contact:
Tom Langford, Feinstein Kean Healthcare
[email protected]
617-761-6775
Investor Contact:
Matthew Clawson, W2O Group
[email protected]
949-370-8500
